Tcipatent Report 2016 Weeks 21-24
Reports comprise records taken from the Online Database. Report Types:- 4-Weekly Reports published every 4 weeks showing the latest records added to the database – text-searchable PDFs, published since 1 January 2014. Back issues available. Bespoke Reports from the Database using selected criteria, e.g. by Drug, Patentee etc. (contact us for prices) Sample report contents: Axitinib, Bepridil, Canagliflozin, Carfilzomib, Caspofungin, Ceftolozane, Ceftolozane, Ceftolozane, Ceftolozane, Cytarabine, Daclatasvir, Docetaxel, Esomeprazole, Gadobutrol, Gemcitabine, Glycopyrronium bromide, Lansoprazole, Ledipasvir, Lurasidone, Metyrapone, Olmutinib, Ospemifene, Ospemifene, Pantoprazole, Rabeprazole, Regorafenib, Sapropterin, Sitagliptin, Sofosbuvir
Reports comprise records taken from the Online Database. Report Types:-
4-Weekly Reports published every 4 weeks showing the latest records added to the database – text-searchable PDFs, published since 1 January 2014. Back issues available.
Bespoke Reports from the Database using selected criteria, e.g. by Drug, Patentee etc. (contact us for prices)
Sample report contents:
Axitinib, Bepridil, Canagliflozin, Carfilzomib, Caspofungin, Ceftolozane, Ceftolozane, Ceftolozane, Ceftolozane, Cytarabine, Daclatasvir, Docetaxel, Esomeprazole, Gadobutrol, Gemcitabine, Glycopyrronium bromide, Lansoprazole, Ledipasvir, Lurasidone, Metyrapone, Olmutinib, Ospemifene, Ospemifene, Pantoprazole, Rabeprazole, Regorafenib, Sapropterin, Sitagliptin, Sofosbuvir
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Marketed Drug Process Patent <strong>Report</strong><br />
[Extracted from the Claimed Intermediate Structure Searchable Database]<br />
<strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
© The Claimed Intermediate • www.tcipatent.com
This Claimed Intermediate <strong>Report</strong> is compiled from The<br />
Claimed Intermediate Database entries.<br />
The <strong>Report</strong>s cover new DE, EP, FR, GB, US and WO patent<br />
specifications concerned with Process Patents for named<br />
Marketed Pharmaceutical Drugs and published as a Four-<br />
Weekly <strong>Report</strong>. Earlier Process Patents for named Marketed<br />
Pharmaceutical Drugs will be included on an ongoing basis for<br />
specific drugs in a Drug Process Patent History <strong>Report</strong>. The<br />
Claimed Intermediate Database of Pharmaceutical Process<br />
Patents for Marketed Pharmaceutical Drugs provides up-todate<br />
comprehensive data for such specific drugs.<br />
Due to the number of languages encountered in patent<br />
specifications, it is not always possible to provide an entry.<br />
However, these will be included in The Claimed<br />
Intermediate Database of Pharmaceutical Process Patents<br />
for Marketed Pharmaceutical Drugs when an inhouse<br />
readable language patent family equivalent emerges (eg a<br />
published EP patent specification).<br />
Only new patent specifications, i.e. first equivalent<br />
specification published (exclusions above), will be included<br />
in the <strong>Report</strong>s and Database. This is to avoid multiple<br />
equivalent ‘family’ specifications being reported. Such<br />
equivalent ‘family’ specifications may be identified via free<br />
or commercial patent equivalent databases.<br />
With regard to the Drug Process Patent History <strong>Report</strong>,<br />
the drugs will be selected inhouse. However, requests for<br />
specific drugs will be welcomed and included under<br />
appropriate anonymity to protect commercial interests.<br />
Structures visible to 300+ zoom.<br />
Accuracy is paramount in identifying such Process Patents and<br />
everything is done to provide a full and complete report.<br />
However, due in particular to the vagaries of various Patent<br />
Classification systems, it may not always be possible to give<br />
such full and complete reports. Where omissions or errors<br />
have been made these would not have been done intentionally<br />
and checks will be made from time to time to review the patent<br />
documents inspected and where such omissions or errors are<br />
noted or pointed out these will be included in The Claimed<br />
Intermediate Database of Pharmaceutical Process Patents for<br />
Marketed Pharmaceutical Drugs which will be amended<br />
accordingly. Usual publishing terms and conditions apply.<br />
© The Claimed Intermediate • www.tcipatent.com
Contents: <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Page<br />
1<br />
2<br />
3<br />
4<br />
5<br />
6<br />
7<br />
8<br />
9<br />
10<br />
11<br />
12<br />
13<br />
14<br />
15<br />
16<br />
17<br />
18<br />
19<br />
20<br />
<strong>21</strong><br />
22<br />
Drug Name<br />
Anagliptin<br />
Buprenorphine<br />
Canagliflozin<br />
Ceritinib<br />
Daclatasvir<br />
Darunavir<br />
Efinaconazole<br />
Emtricitabine<br />
Ibrutinib<br />
Idelalisib<br />
Ivabradine<br />
Ledipasvir<br />
Luliconazole<br />
Micafungin ( Anidulafungin )<br />
Miglustat<br />
Obeticholic acid<br />
Palbociclib<br />
Palbociclib<br />
Praziquantel<br />
Revaprazan<br />
Sertraline<br />
Tafluprost ( Lubiprostone )<br />
Patentee<br />
Suzhou Jonathan New Material Technology Co., Ltd.<br />
Siegfried AG<br />
Cipla Limited<br />
Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.<br />
Sun Pharmaceutical Industries Limited<br />
Lupin Limited<br />
Mapi Pharma Ltd.<br />
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<br />
Sun Pharmaceutical Industries Limited<br />
Ratiopharm GmbH<br />
Richter Gedeon NYRT.<br />
Shanghai Forefront Pharmaceutical., Ltd.<br />
Glenmark Pharmaceuticals Limited<br />
DSM Sinochem Pharmaceuticals Netherlands B.V.<br />
Navinta LLC et al<br />
Dextra Laboratories Limited<br />
Suzhou Miracpharma Technology Co., Ltd and Zheren Pharmaceutical Nanjing Co., Ltd<br />
Suzhou Miracpharma Technology Co., Ltd and Zheren Pharmaceutical Nanjing Co., Ltd<br />
Merck Patent GmbH<br />
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.<br />
Council of Scientific & Industrial Research<br />
Apotex Inc.
Contents: <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Page<br />
23<br />
<strong>24</strong><br />
25<br />
26<br />
27<br />
28<br />
29<br />
30<br />
31<br />
Drug Name<br />
Tedizolid phosphate<br />
Telmisartan<br />
Teneligliptin<br />
Trazodone<br />
Treprostinil<br />
Vemurafenib<br />
Vildagliptin<br />
Vortioxetine<br />
Vortioxetine<br />
Patentee<br />
Sun Pharmaceutical Industries Limited<br />
Virginia Commonwealth University<br />
Sun Pharmaceutical Industries Limited<br />
Suzhou Jonathan New Material Technology Co., Ltd.<br />
Everlight Chemical Industrial Corporation<br />
Shilpa Medicare Limited<br />
Suzhou Jonathan New Material Technology Co., Ltd.<br />
Dipharma Francis S.r.l<br />
Megafine Pharma (P) Ltd.
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Anagliptin<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078109<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119CN10663657<br />
Patentee: Suzhou Jonathan New Material Technology Co., Ltd.<br />
Patent Description: Anagliptin appears to be obtained via the prepared intermediate (2S)-N-chloroacetyl-2-cyanopyrrolidine. Vildagliptin also appears to be prepared.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 1
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Buprenorphine<br />
Patent Specification<br />
Number: EP 3023427<br />
Publication Date:<br />
<strong>2016</strong>-05-25<br />
First Filing<br />
Priority Details: 20141119EP193857<br />
Patentee: Siegfried AG<br />
Patent Description: Buprenorphine is obtained from oripavine via N-alkylation, 7-acetylation, 7-hydroxyalkylation and etheno reduction.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 2
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Canagliflozin<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/083790<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141125IN3731<br />
Patentee: Cipla Limited<br />
Patent Description: Canagliflozin is obtained via prepared claimed intermediate IIIc.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 3
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Ceritinib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/081538<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141118US62/081119<br />
Patentee: Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.<br />
Patent Description: Ceritinib is obtained via the N-arylation reaction as shown. X-ray defined ceritinib crystalline Form Beta is claimed.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 4
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Daclatasvir<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079697<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119IN3344/DEL<br />
Patentee: Sun Pharmaceutical Industries Limited<br />
Patent Description: Daclatasvir is obtained via the preparation of intermediate II.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 5
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Darunavir<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/092525<br />
Publication Date:<br />
<strong>2016</strong>-06-16<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>2IN3990/MUM<br />
Patentee: Lupin Limited<br />
Patent Description: Darunavir is obtained by hydrogenating nitro-darunavir.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 6
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Efinaconazole<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079728<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141123US62/083233<br />
Patentee: Mapi Pharma Ltd.<br />
Patent Description: Efinaconazole is obtained via prepared claimed intermediates 3 and 4 and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 7
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Emtricitabine<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078584<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141118CN10660872<br />
Patentee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<br />
Patent Description: Emtricitabine is obtained purified by separating out emtricitabine benzoate from an aqueous solution.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 8
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Ibrutinib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079693<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119IN3343/DEL<br />
Patentee: Sun Pharmaceutical Industries Limited<br />
Patent Description: Ibrutinib is obtained via claimed intermediates VI and VIII and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 9
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Idelalisib<br />
Patent Specification<br />
Number: EP 3031808<br />
Publication Date:<br />
<strong>2016</strong>-06-15<br />
First Filing<br />
Priority Details: 20141209EP196931<br />
Patentee: Ratiopharm GmbH<br />
Patent Description: Idelalisib is obtained as hydrochloride salt via N-deprotection and crystallisation with hydrochloric acid. X-ray defined idelalisib hydrochloride salt is claimed.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 10
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Ivabradine<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079684<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119HU545<br />
Patentee: Richter Gedeon NYRT.<br />
Patent Description: Ivabradine is obtained via prepared intermediate II from 3,4-dimethoxyphenylacetic acid (III).<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 11
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Ledipasvir<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078505<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141120CN10668957<br />
Patentee: Shanghai Forefront Pharmaceutical., Ltd.<br />
Patent Description: Ledipasvir is obtained via the preparation of a fluorene ethyl ketone which is fluorinated with eg N-fluorobenzenesulfonimide (NFSI).<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 12
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Luliconazole<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/09<strong>24</strong>78<br />
Publication Date:<br />
<strong>2016</strong>-06-16<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>2IN3992/MUM<br />
Patentee: Glenmark Pharmaceuticals Limited<br />
Patent Description: Luliconazole is obtained as shown and purified via preparation of an acid addition salt. X-ray defined luliconazole hydrochloride is claimed.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 13
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Micafungin ( Anidulafungin )<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/091746<br />
Publication Date:<br />
<strong>2016</strong>-06-16<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>1EP197387<br />
Patentee: DSM Sinochem Pharmaceuticals Netherlands B.V.<br />
Patent Description: Micafungin is obtained via the acylation of FR 179642 with prepared claimed intermediate (2). The preparation of anidulafungin is referred to.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 14
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Miglustat<br />
Patent Specification<br />
Number: EP 3031800<br />
Publication Date:<br />
<strong>2016</strong>-06-15<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>1US62/90783<br />
Patentee: Navinta LLC et al<br />
Patent Description: Miglustat is obtained with high purity without the use of a flash column chromatography or ion exchange.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 15
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Obeticholic acid<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079517 + WO <strong>2016</strong>/079518 + W<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119GB20593 + 20141119GB20594<br />
Patentee: Dextra Laboratories Limited<br />
Patent Description: Obeticholic acid is obtained via the dioxo reduction of claimed intermediate (I) and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 16
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Palbociclib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/082605<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141126CN106930911<br />
Patentee: Suzhou Miracpharma Technology Co., Ltd and Zheren Pharmaceutical Nanjing Co., Ltd<br />
Patent Description: Palbociclib is obtained via ring-closing, substitution, condensation and hydrolysis reactions.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 17
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Palbociclib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/082604<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141126CN106912330<br />
Patentee: Suzhou Miracpharma Technology Co., Ltd and Zheren Pharmaceutical Nanjing Co., Ltd<br />
Patent Description: Palbociclib is obtained via ring-closing, substitution, condensation and dehydrogenation reaction steps.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 18
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Praziquantel<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078765<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 201411<strong>21</strong>EP3933<br />
Patentee: Merck Patent GmbH<br />
Patent Description: (R)-Praziquantel is obtained via (R)-praziquanamine obtained from a salt of (R)-praziquanacetamide with a >/=14C chiral 2-arylpropionic acid, eg (S)-naproxen.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 19
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Revaprazan<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078542<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119CN10665839<br />
Patentee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.<br />
Patent Description: Revaprazan is obtained via cyclisation, chlorination and N-arylation.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 20
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Sertraline<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/088138<br />
Publication Date:<br />
<strong>2016</strong>-06-09<br />
First Filing<br />
Priority Details: 20141201IN3482/DEL<br />
Patentee: Council of Scientific & Industrial Research<br />
Patent Description: Sertraline is obtained via prepared claimed intermediates Ia and Ib and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page <strong>21</strong>
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Tafluprost ( Lubiprostone )<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/090461<br />
Publication Date:<br />
<strong>2016</strong>-06-16<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>0US62/090035<br />
Patentee: Apotex Inc.<br />
Patent Description: Tafluprost is obtained via claimed crystalline 1-adamantanamine intermediate 6a. Other process intermediates are claimed. The preparation of lubiprostone is referred to.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 22
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Tedizolid phosphate<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/088103<br />
Patentee: Sun Pharmaceutical Industries Limited<br />
Patent Description: Tedizolid phosphate is obtained as shown.<br />
Publication Date:<br />
<strong>2016</strong>-06-09<br />
First Filing<br />
Priority Details: 20141205IN3548/DEL<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 23
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Telmisartan<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/089845<br />
Publication Date:<br />
<strong>2016</strong>-06-09<br />
First Filing<br />
Priority Details: 20141201US62/085842<br />
Patentee: Virginia Commonwealth University<br />
Patent Description: Telmisartan is obtained via a Suzuki cross-coupling reaction between the prepared trifluoroborate intermediate and 2-bromo-1-methylbenzimidazole.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page <strong>24</strong>
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Teneligliptin<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079699<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119IN3342/DEL<br />
Patentee: Sun Pharmaceutical Industries Limited<br />
Patent Description: Tenelegliptin is obtained via the aqueous phase preparation of (4R)-1-(tert-butoxycarbonyl)-4-hydroxy-L-proline - intermediate IV.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 25
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Trazodone<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078107<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119CN10663127<br />
Patentee: Suzhou Jonathan New Material Technology Co., Ltd.<br />
Patent Description: Trazodone is obtained via the preparation of the intermediate 1-(3-chlorophenyl)-4-(3-chloropropane)piperazine.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 26
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Treprostinil<br />
Patent Specification<br />
Number: US <strong>2016</strong>/0152548<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141201TW103141569<br />
Patentee: Everlight Chemical Industrial Corporation<br />
Patent Description: Treprostinil is obtained via claimed intermediates (II) and (VIII-I) and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 27
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Vemurafenib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/083956<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141129IN5990/CHE<br />
Patentee: Shilpa Medicare Limited<br />
Patent Description: Vemurafenib is obtained and purified via a trifluoromethane sulfonic acid salt.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 28
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Vildagliptin<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078109<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119CN10663657<br />
Patentee: Suzhou Jonathan New Material Technology Co., Ltd.<br />
Patent Description: Vildagliptin appears to be obtained via the prepared intermediate (2S)-N-chloroacetyl-2-cyanopyrrolidine. Anagliptin also appears to be prepared.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 29
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Vortioxetine<br />
Patent Specification<br />
Number: EP 3023417<br />
Publication Date:<br />
<strong>2016</strong>-05-25<br />
First Filing<br />
Priority Details: 201411<strong>21</strong>ITMI142018<br />
Patentee: Dipharma Francis S.r.l<br />
Patent Description: Vortioxetine is obtained via claimed intermediate IV. Other intermediates are claimed.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 30
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Vortioxetine<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079751<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141117IN3612/MUM<br />
Patentee: Megafine Pharma (P) Ltd.<br />
Patent Description: Vortioxetine is obtained via the reaction of prepared 2-[(2,4-dimethylphenyl)thio]aniline with a dialkyl amine compound. X-ray defined crystalline vortioxetine<br />
hydrobromide Form M1 is claimed.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 31
For a subscription to the Text/Structure searchable Database visit the Website or contact 'info' as below<br />
www.tcipatent.com<br />
info@tcipatent.com<br />
T: +44 (0) 1273 736 080<br />
© <strong>Tcipatent</strong> Ltd • www.tcipatent.com
Change language